Skip to main content
. Author manuscript; available in PMC: 2021 Feb 15.
Published in final edited form as: Cancer Res. 2020 Jun 19;80(16):3372–3382. doi: 10.1158/0008-5472.CAN-20-0056

Figure 2.

Figure 2

A) Estimation of the net growth rate of sensitive cells using drug combination data. 1) Viable cell counts under different drug concentrations of alpelisib and neratinib. 2) Net growth rate of sensitive cells as a function of the different drug concentrations. 3) Heatmap of type-0 birth rate parameters under different drug concentrations. B) Model fitting results for neratinib and alpelisib drug combination study, where the surface from type-0 (sensitive to both drugs) cell birth rates is characterized with a Generalized Additive Model (GAM) and the birth rates from resistant cell types (type-1 is neratinib-resistant and type-2 is alpelisib-resistant) are described with different non-linear models included in ACESO (exponential, Weibull, log-logistic…). The specific equation and parameter values for each curve are summarized in Table 1.